Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementBlue Cross Blue Shield Louisiana Opioid Prior Auth…
    Ask Trek AI about this page
    Currentblue cross blue shield - louisianaPolicy N/A

    Opioid Coverage and Prior Authorization Policy

    Customize your policy alerts

    Sign up for all blue cross blue shield - louisiana policy alerts

    Know when blue cross blue shield - louisiana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, safety edits, and coverage criteria for short-acting and long-acting opioid prescriptions for Blue Cross and Blue Shield of Louisiana members; applies to prescribers and pharmacies handling member opioid prescriptions.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyOpioid Coverage and Prior Authorization Policy
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization for short-acting opioid fills longer than 7 days or cumulative >21 days within 60 days and for new users of long-acting opioids.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    47%+reduction in opioid prescriptions per 1,000 members since 2016
    51%+reduction in opioid units per member per month since 2016
    7 daysmax short-acting fill w/o PA
    21 days/60 dayscumulative threshold triggering PA

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Short-acting opioid prior authorization

    Prior authorization is required unless the requested opioid is used for cancer pain or end-of-life care, OR when ALL of the following are met:

    Exception: Requested opioid is used to treat cancer pain OR end-of-life care

    Claims history or provider information may establish exception

    Standard PA criteria: 1) Prescriber certifies that there is an active treatment plan that includes other pharmacological and nonpharmacological agents for pain relief (as appropriate); 2) Prescriber certifies there is a documented patient-prescriber agreement addressing prescription management, diversion, doctor/pharmacy shopping, and use of other substances; 3) Prescriber has completed an addiction risk assessment; 4) If the requested drug is levorphanol 2 mg or 3 mg tablets ONLY: patient has tried and failed TWO specified short-acting opioid products unless clinical evidence or patient history indicates those products will be ineffective or cause an adverse reaction.

    All listed conditions must be met

    Long-acting opioid prior authorization (new users)

    Prior authorization required for new users unless the requested opioid is used to treat cancer pain or end-of-life care, OR when ALL of the following are met:

    Exception: Requested opioid is utilized to treat cancer pain OR end-of-life care

    Claims history or provider information may establish exception

    Standard PA criteria for long-acting opioids: 1) Patient requires around-the-clock pain control; 2) Prescriber certifies there is an active treatment plan that includes other pharmacological and nonpharmacological agents for pain relief (as appropriate); 3) Prescriber certifies there is a documented patient-prescriber agreement addressing prescription management, diversion, doctor/pharmacy shopping, and use of other substances; 4) Prescriber has completed an addiction risk assessment; 5) For specified long-acting agents (e.g., Arymo ER, Hysingla ER, Dolophine, Duragesic Patch, Embeda, Exalgo, Kadian, MS Contin, Nucynta ER, Opana ER, Branded Oxycodone ER, Xartemis XR, Xtampza ER, Zohydro ER, certain generic ER hydrocodone, specified fentanyl patch strengths, Morphabond ER): patient has tried and failed at least TWO listed long-acting opioid alternatives (Belbuca, generic buprenorphine patch, generic fentanyl patch at listed strengths, generic hydromorphone ER, generic hydrocodone ER tabs, generic methadone/methadose, generic morphine ER/CR, or OxyContin) unless clinical evidence or patient history indicates the alternatives will be ineffective or cause an adverse reaction; 6) If the requested drug is Butrans patch (any listed strength): patient has tried and failed generic buprenorphine patch AND Belbuca unless clinical evidence or patient history indicates these products will be ineffective or cause an adverse reaction.

    All listed conditions must be met; agent-specific step requirements apply

    Coverage decisions recognize exceptions for cancer-related pain and end-of-life care. When the requested opioid is being used to treat cancer pain or for end-of-life care, the prior authorization requirements do not apply if the member’s claims history or information provided by the treating provider establishes that exception.

    When an exception is not established, prior authorization requirements apply. For short-acting opioids this includes fills longer than a 7-day supply or a cumulative supply exceeding 21 days within 60 days. For long-acting opioids, prior authorization is required for new users. Providers should submit claims history or attestations in the medical record as needed to document cancer or end-of-life status so the exception can be evaluated.

    Coding and Thresholds

    Short-acting opioid prior auth thresholds
    Trigger for short-acting opioid PASingle fill longer than a 7-day supply OR cumulative supply exceeding 21 days within any 60-day period
    ExceptionsMembers with cancer pain or receiving end-of-life care may be exempt based on claims history or provider information
    Action requiredSubmit prior authorization when either threshold is exceeded

    Provider Actions and Requirements

    Prior Authorization

    Prior authorization required for certain short- and long-acting opioids

    Prior authorization is required for short-acting opioid fills that exceed a 7-day supply or a cumulative 21-day supply within 60 days, and for new-user long-acting opioid prescriptions; this requirement does not apply when the requested opioid is used to treat cancer pain or for end-of-life care (exceptions may be established from claims history or provider information). Providers must obtain PA before dispensing when these thresholds or new-user long-acting opioid requests apply to avoid claim denial or delay.

    • Short-acting opioids: PA required for fills longer than a 7‑day supply or cumulative >21 days within 60 days.
    • Long-acting opioids: PA required for new users.
    • Cancer pain and end-of-life care are exceptions when supported by claims or provider information.
    Step Therapy

    Step therapy: required trials and failures for specific opioid agents

    For specified products the prescriber must document trial-and-failure of alternative opioid agents before approval: levorphanol 2 mg/3 mg tablets require failure of TWO listed short-acting opioids; many long-acting agents require failure of at least TWO listed long-acting alternatives; Butrans patch specifically requires failure of the generic buprenorphine patch AND Belbuca, unless clinical evidence or history indicates ineffectiveness or adverse reaction.

    Definitions

    Short-acting opioids — examples & PA note
    Examples of short-acting opioidsPercocet and generics; Lortab and generics; codeine; oxycodone
    PA applicabilityThese agents are subject to prior authorization when fills exceed a 7-day supply or cumulative 21 days within 60 days
    Related safety editsTylenol-containing combos limited to 3 g/day; ibuprofen combos limited to 5 tabs/day; aspirin combos limited to 4 g/day
    Long-acting opioids — examples & PA requirement
    Examples of long-acting opioidsButrans (buprenorphine patch); fentanyl patch; OxyContin; MS Contin; morphine ER; oxycodone ER
    PA requirement for new usersPrior authorization is required for new users of long-acting opioids

    Background

    Opioid misuse is an ongoing statewide concern. In response, Blue Cross and Blue Shield of Louisiana has implemented opioid coverage controls designed to limit initiation to chronic opioid use and to reduce overall opioid supply, aligning coverage practices with clinical guidance and state efforts to improve prescribing safety.

    These controls include safety edits and prior authorization requirements for both short-acting and long-acting opioids — for example, prior authorization is required for short-acting opioid fills that exceed a 7-day supply or a cumulative supply of 21 days within 60 days, and for new users of long-acting opioid products. Additional information about drug coverage and the plan’s Covered Drug List is available at the payer’s member resources.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyOpioid Coverage and Prior Authorization Policy
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization for short-acting opioid fills longer than 7 days or cumulative >21 days within 60 days and for new users of long-acting opioids.
    SourceLink
    On This Page
    Coverage CriteriaCoding and ThresholdsProvider Actions and RequirementsDefinitionsBackground
    • Levorphanol 2 mg/3 mg tablets: try and fail TWO specified short-acting products (listed in policy) unless contraindicated.
    • Several long-acting agents (e.g., Arymo ER, Hysingla ER, Duragesic, MS Contin, Xartemis XR, Xtampza ER, Zohydro ER, etc.): try and fail at least TWO listed long-acting opioid alternatives unless contraindicated.
    • Butrans patch (all strengths): must try and fail generic buprenorphine patch AND Belbuca unless clinical evidence/history justifies exception.
    Documentation Required

    Required documentation to support prior authorization requests

    Prescribers must document and certify in the medical record that an active multimodal treatment plan is in place, that a patient–prescriber agreement addressing prescription management/diversion/pharmacy shopping/substance use is documented, and that an addiction risk assessment has been completed; additionally, document trials and failures of required alternative agents when step therapy applies.

    • Certify active treatment plan including other pharmacological and nonpharmacological agents.
    • Document patient–prescriber agreement addressing prescription management, diversion, doctor/pharmacy shopping, and substance use.
    • Complete and document an addiction risk assessment.
    • Document trials and failures of specified alternative opioids when required by agent-specific criteria.
    Denial Risk

    Denial triggers: supply thresholds and unmet PA/step requirements

    Requests will be denied if they exceed short-acting thresholds (fills longer than a 7‑day supply or cumulative >21 days within 60 days) or if a long-acting opioid is initiated for a new user without meeting the PA criteria or required step-therapy exceptions.

    • Exceeding short-acting opioid limits—>7 days per fill or >21 days cumulative in 60 days—triggers denial unless exception applies.
    • Initiation of long-acting opioids for new users without meeting all PA criteria (including required trials where applicable) can result in denial.
    ExceptionsMembers with cancer pain or receiving end-of-life care may be exempt based on claims history or provider information
    Step/agent-specific requirementsMany long-acting agents require trials/failures of listed alternatives before approval (see policy for specifics)